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Experimental Procedures 
General. Unless otherwise noted, all chemicals and reagents were obtained from commercial 
suppliers (Sigma-Aldrich, VWR, Alfa Aesar) and used without further purification. Silica gel 
chromatography was carried out using AMD Silica Gel 60, 230-400 mesh. 1H and 13C NMR 
spectra were recorded on a Varian Inova 300 MHz or 500 MHz, or Bruker Prodigy 400 MHz 
instrument, in CDCl3 and are referenced to residual protio solvent signals. Data for 1H NMR are 
reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, p = pentet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, ddd = 
doublet of doublet of doublets), coupling constant (Hz), integration. Sonication was performed 
using a Qsonica Q500 sonicator. High-resolution mass spectra were obtained at the California 
Institute of Technology Mass Spectral Facility. Synthetic reactions were monitored using thin 
layer chromatography (Merck 60 gel plates) using a UV-lamp for visualization. Substrates were 
purchased from commercial suppliers. Tosyl azide was prepared according to de Nanteuil and 
Waser.1 
 
Chromatography. Analytical high-performance liquid chromatography (HPLC) was carried out 
using an Agilent 1200 series instrument and a Kromasil 100 C18 column (4.6 x 50 mm, 5 µm) 
with water and acetonitrile as the mobile phase. Semi-preparative HPLC was performed using an 
Agilent XDB-C18 column (9.4 x 250 mm, 5 µm) with water and acetonitrile as the mobile phase. 
Analytical chiral HPLC was conducted using a supercritical fluid chromatography (SFC) system 
with isopropanol and liquid CO2 as the mobile phase. Product enantiomers were separated using 
a Chiralpak AS column (4.6 x 150 mm, 5 µm) from Chiral Technologies Inc. 
 
Cloning and site-directed mutagenesis. pET22b(+) was used as a cloning and expression 
vector for all enzymes described in this study. Site-directed mutagenesis was performed using a 
modified QuikChangeTM
 
mutagenesis protocol.2 The PCR products were digested with DpnI, gel 
purified, and the gaps were repaired using Gibson MixTM.3 The ligation mixture was used to 
directly transform E. coli strain BL21 E. cloni (Lucigen). 
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Determination of P411 concentration. The concentration of P411 enzymes in whole cell 
experiments was determined from ferrous carbon monoxide binding difference spectra using the 
previously reported extinction coefficient for serine-ligated enzymes (ε = 103,000 M–1 cm–1).4 
The concentration of purified P411 enzymes was determined by quantifying the amount of free 
hemin present using the pyridine/hemochrome assay and the published extinction coefficient (ε = 
191,500 M–1 cm–1).5 
 
Expression and amination bioconversions using whole cells. E. coli BL21 E. cloni cells 
carrying a plasmid encoding a P411 variant were grown overnight in 5 mL Luria-Bertani 
medium with 0.1 mg/mL
 
ampicillin (LBamp, 37 ºC, 250 rpm). The preculture was used to 
inoculate 45 mL of Hyperbroth (HB) medium (prepared from AthenaES© powder, 0.1 mg/mL
 
ampicillin) in a 125-mL Erlenmeyer flask; this culture was incubated at 37 ºC, 230 rpm for 2 h. 
Cultures were then cooled on ice (20 min), and expression was induced with 0.5 mM IPTG and 
1.0 mM 5-aminolevulinic acid (final concentrations). Expression was conducted at room 
temperature (23 ºC), at 130 rpm, for 16–18 h. Cultures were then centrifuged (2,600 x g, 10 min, 
4 ºC), and the pellets were resuspended to an OD600 of 30 in M9-N minimal media (no nitrogen). 
Aliquots of the cell suspension (4 mL) were used to determine the P411 expression level after 
lysis by sonication. 
For amination bioconversions, the cells (OD600 of 30 in M9-N media) were degassed by 
sparging with argon in sealed 6-mL crimp vials for at least 40 minutes. Separately, a glucose 
solution (250 mM in M9-N) was degassed by sparging with argon for at least 10 minutes. An 
oxygen depletion system (20 µL of a stock solution containing 14,000 U/mL catalase and 1,000 
U/mL glucose oxidase in 0.1 M KPi, pH 8.0) was added to 2-mL crimp vials. All solutions were 
uncapped and transferred into an anaerobic chamber. Resuspended cells (320 µL) were added to 
the vials, followed by glucose (40 µL, 250 mM in M9-N), alkane (10 µL of a DMSO stock), and 
tosyl azide (10 µL of a DMSO stock). Final concentrations were typically 2.5–5.0 mM alkane, 
5.0 mM tosyl azide, and 25 mM glucose; final reaction volume was 400 µL. The vials were 
sealed, removed from the anaerobic chamber, and shaken at room temperature and 40 rpm for 
16–20 h. Reactions under aerobic conditions were performed by combining resuspended cells 
(320 µL), glucose (40 µL, 250 mM in M9-N), oxygen depletion system (20 µL, or 20 µL M9-N), 
alkane (10 µL, 200 mM in DMSO), and tosyl azide (10 µL, 200 mM in DMSO) on the benchtop, 
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without any argon sparging (final reaction volume 400 µL). The reactions were quenched by 
addition of acetonitrile (400 µL) and internal standard (10 µL of a DMSO stock). This mixture 
was then transferred to a microcentrifuge tube and centrifuged at 20,000 x g for 10 minutes. The 
supernatant was transferred to a vial and analyzed by HPLC. 
 
Reaction screening in 96-well plate format. Site-saturation libraries were generated employing 
the “22c-trick” method.2
 E. coli libraries were cultured in LBamp (300 µL/well) at 37 ºC, 220 rpm 
and 80% relative humidity overnight. Hyperbroth medium (1000 µL/well, 0.1 mg/mL
 
ampicillin) 
was inoculated with the preculture (50 µL/well) and incubated at 37 ºC, 220 rpm, 80% humidity 
for 3 h. The plates were cooled on ice for 30 minutes, and then expression was induced with 0.5 
mM IPTG and 1.0 mM 5-aminolevulinic acid (final concentrations). Expression was conducted 
at 20 ºC and 120 rpm for 24 h. The cells were pelleted (3,000 x g, 5 min, 4 ºC) and resuspended 
in the oxygen depletion system (20 µL/well). The 96-well plate was then transferred to an 
anaerobic chamber. In the anaerobic chamber, argon-sparged reaction buffer (50 mM glucose in 
M9-N, 300 µL/well) was added, followed by the alkane (10 µL/well, 200 mM in DMSO) and 
tosyl azide (10 µL/well, 200 mM in DMSO). The plate was sealed with an aluminum foil, 
removed from the anaerobic chamber, and shaken at 40 rpm. After 16–20 h, the seal was 
removed and acetonitrile (400 µL/well) and internal standard (10 µL/well of a DMSO stock) 
were added. The wells were mixed, the plate was centrifuged (5,000 x g, 10 min), and the 
supernatant was filtered through an AcroPrep 96-well filter plate (0.2 µm) into a shallow-well 
plate for HPLC analysis. 
 
Protein purification. E. coli BL21 E. cloni cells carrying a plasmid encoding a P411 variant 
were grown overnight in 25 mL LBamp (37 ºC, 250 rpm). Hyperbroth medium (630 mL, 0.1 
mg/mL
 
ampicillin) in a 1-L flask was inoculated with 25 mL of the preculture and incubated at 
37 ºC and 230 rpm for 2.5 h (to OD600 ca. 1.8). Cultures were then cooled on ice (30 min) and 
induced with 0.5 mM IPTG and 1.0 mM 5-aminolevulinic acid (final concentrations). Expression 
was conducted at 23 ºC, 130 rpm, for 16–20 h. Cultures were then centrifuged (5,000 x g, 8 min, 
4 ºC) and the cell pellets frozen at –20 ºC. For purification, frozen cells from two such cultures 
were resuspended in buffer A (25 mM tris, 20 mM imidazole, 100 mM NaCl, pH 7.5, 4 mL/g of 
cell wet weight), loaded with hemin (1 mg/gram wet cell weight) and powdered DNaseI, and 
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lysed by sonication. To pellet cell debris, lysates were centrifuged (20,000 x g, 20 min, 4 ºC). 
Proteins were expressed in a construct containing a 6x-His tag and purified using a nickel NTA 
column (1 mL HisTrap HP, GE Healthcare, Piscataway, NJ) using an AKTA or AKTAxpress 
purifier FPLC system (GE healthcare). P411 enzymes were eluted with a linear gradient from 
100% buffer A to 100% buffer B (25 mM tris, 300 mM imidazole, 100 mM NaCl, pH 7.5) over 
10 column volumes. 
 Proteins used for crystallography were subjected to an additional ion-exchange 
purification step. For these proteins, fractions were pooled and subjected to three exchanges of 
anion exchange buffer A (25 mM tris-HCl, pH 7.5) using centrifugal spin filters (10 kDa 
molecular weight cut-off, Amicon Ultra, Merck Millipore). Next, the protein was loaded onto an 
anion exchange Q Sepharose column (HiTrapTM Q HP, GE Healthcare) and purified using an 
AKTA or AKTAexpress purifier FPLC system (GE healthcare). The enzyme was eluted from the 
Q-column by running a gradient from 0 to 0.5 M NaCl over 10 column volumes. Fractions 
containing the enzyme were pooled, concentrated, and exchanged into storage buffer (25 mM 
tris-HCl, 25 mM NaCl, pH 7.5) as before. Subsequently, the concentrated protein was aliquoted, 
flash-frozen on powdered dry ice, and stored at –80 ºC.  Protein concentrations were determined 
via Bradford assay with a bovine serum albumin standard curve.  
 Proteins used for other purposes were eluted from the Ni-NTA column as described 
above, pooled, concentrated, and subjected to three exchanges of phosphate buffer (0.1 M KPi, 
pH 8.0) using centrifugal filters (10 kDa molecular weight cut-off, Amicon Ultra, Merck 
Millipore) to remove excess salt and imidazole. Concentrated proteins were aliquoted, flash-
frozen on powdered dry ice, and stored at –80 or –20 ºC. 
 
Amination bioconversions using purified protein. Aliquots of phosphate buffer (260 µL 0.1 M 
KPi, pH 8.0) and NADPH (40 µL, 100 mM), or multiples thereof, were combined in a 6-mL 
crimp vial and degassed by sparging with argon for at least 30 minutes. Separately, a glucose 
solution (250 mM in 0.1 M KPi, pH 8.0) was also degassed in the same manner. Crimp vials (2 
mL) were each charged with the oxygen depletion system (20 µL of a stock solution containing 
14,000 U/mL catalase and 1,000 U/mL glucose oxidase in 0.1 M KPi, pH 8.0). After degassing 
was complete, all solutions, 2-mL crimp vials, and purified protein (100 µM in 0.1 M KPi, pH 
8.0), kept on ice, were brought into the anaerobic chamber. Glucose solution (40 µL), NADPH 
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solution (300 µL), and purified protein (20 µL of 100 µM stock solution) were added to each 2-
mL vial. Reaction vials were then charged with alkane (10 µL, 200 mM in DMSO) and tosyl 
azide (10 µL, 200 mM in DMSO). Final concentrations were typically 5 mM alkane, 5 mM tosyl 
azide, 10 mM NADPH, 25 mM glucose, and 5 µM P411; final reaction volume was 400 µL. The 
vials were sealed, removed from the anaerobic chamber, and shaken at room temperature and 40 
rpm for 16–20 h. The reactions were quenched by addition of acetonitrile (400 µL) and internal 
standard (10 µL of a DMSO stock). This mixture was then transferred to a microcentrifuge tube 
and centrifuged at 20,000 x g for 10 minutes. The supernatant was transferred to a vial and 
analyzed by HPLC. Sodium dithionite (5 mM) was used as the reductant instead of NADPH for 
reactions with hemin and myoglobin. 
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Supplementary Table 1. C–H amination of 4-ethylanisole with variants of cytochrome 
P450BM3.a 
 
Variant Mutations relative to wild-type P450BM3 Yield 
pET22b(+) vector N/A N.D. 
P450BM3 None N.D. 
P411BM3 C400S N.D. 
P411BM3 T268A T268A, C400S N.D. 
P411BM3-CIS T438S ("P") V78A, F87V, P142S, T175I, A184V, 
S226R, H236Q, E252G, T268A, A290V, 
L353V, I366V, C400S, T438S, E442K 
N.D. 
P411BM3-CIS T438S A268T V78A, F87V, P142S, T175I, A184V, 
S226R, H236Q, E252G, A290V, L353V, 
I366V, C400S, T438S, E442K 
N.D. 
P411BM3-H2-5-F10 L75A, V78A, F87V, P142S, T175I, 
A184V, S226R, H236Q, E252G, I263A, 
T268A, A290V, L353V, I366V, C400S, 
L437A, E442K 
N.D. 
P411BM3-H2-A-10 L75A, V78A, F87V, P142S, T175I, 
L181A, A184V, S226R, H236Q, E252G, 
T268A, A290V, L353V, I366V, C400S, 
E442K  
N.D. 
P411BM3-H2-4-D4 L75A, V78A, F87V, P142S, T175I, 
M177A, L181A, A184V, S226R, H236Q, 
E252G, T268A, A290V, L353V, I366V, 
N.D. 
Me
NHTs
Me
TsN3
P450BM3 variant
whole cellsMeO MeO
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C400S, L437A, E442K 
P411BM3 T268A F87Ab F87A, T268A, C400S N.D.  
P-I263Fb V78A, F87V, P142S, T175I, A184V, 
S226R, H236Q, E252G, I263F, T268A, 
A290V, L353V, I366V, C400S, T438S, 
E442K 
<1% yield 
P-I263F A268T P-I263F A268T N.D. 
P-I263F A328V P-I263F A328V <1% yield 
P-I263F A328V L437Vc P-I263F A328V L437V N.D. 
P-I263F V87A P-I263F V87A 2% yield 
P-I263F V87A A328V P-I263F V87A A328V 2% yield 
P-I263F V87A A328V A82L P-I263F V87A A328V A82L 4% yield 
P-5 P-I263F V87A A328V A268G A82I 14% yield 
P-4 A82L A78V F263Md P-4 A82L A78V F263M 55% yield,  
99% ee 
P-4 A82L A78V F263Yd P-4 A82L A78V F263Y 68% yield,  
61% ee 
P-4 A82L A78V F263L 
(heme domain only) 
P-4 A82L A78V F263L                      
(heme domain only) 
<1% yield 
aReactions performed in whole cells at OD600 = 30 with 5 mM of each substrate; results are the 
average of duplicate reactions. N.D. = none detected. bVariants identified for regioselective 
intramolecular C–H amination.6 cVariant identified for aziridination of styrenes.7 dOther active 
variants identified in the course of evolution of cytochrome P411CHA. 
 
 
 
 		 9 
Supplementary Table 2. C–H amination of 4-ethylanisole performed with hemin or heme-
containing proteins.a 
 
Catalyst Yield 
hemin (25 µM)b N.D. 
hemin (25 µM) + imidazole (1 mM)b N.D. 
hemin (25 µM) + bovine serum albumin (10 µM)b N.D. 
Myoglobin (Mb, equine heart, 10 µM)b N.D. 
Mb H64V V68A (sperm whale, 10 µM)b,c N.D. 
Rhodothermus marinus cytochrome cd N.D. 
Hydrogenobacter thermophilus cytochrome cd N.D. 
Rhodopila globiformis cytochrome cd N.D. 
Rhodothermus marinus cytochrome c V75T M100D M103Ed,e N.D. 
aReactions performed with 5 mM 4-ethylanisole and 5 mM tosyl azide; results are the average of 
duplicate reactions. N.D. = none detected. bPerformed in vitro with 5 mM sodium dithionite. 
cVariant identified for intramolecular C–H amination.8 dPerformed in whole cells at OD600 = 30. 
eVariant identified for carbene Si–H insertion.9 
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Supplementary Table 3. Mutations present in cytochrome P450BM3 variants used in this work. 
Variant Mutations relative to wild-type P450BM3 
P-4 V78A, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, I263F, 
T268G, A290V, A328V, L353V, I366V, C400S, T438S, E442K 
P-4 A82L V78A, A82L, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, 
I263F, T268G, A290V, A328V, L353V, I366V, C400S, T438S, 
E442K 
P-4 A82L A78V A82L, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, I263F, 
T268G, A290V, A328V, L353V, I366V, C400S, T438S, E442K 
P-4 A82L A78V 
F263L 
A82L, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, I263L, 
T268G, A290V, A328V, L353V, I366V, C400S, T438S, E442K 
P-4 A82L A78V 
F263L E267D 
(P411CHA) 
A82L, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, I263L, 
E267D, T268G, A290V, A328V, L353V, I366V, C400S, T438S, 
E442K 
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Supplementary Table 4. Summary of directed evolution for intermolecular C–H amination.a 
Generation Parent enzyme Site-saturation 
libraries evaluated 
Screening 
substrate 
Mutation 
identified 
1 P-4 A82L A78X, L181X, 
F263X, T327X 
4-ethylanisole  A78V  
2 P-4 A82L A78V F263X, T327X 4-ethylanisole F263L 
3a P-4 A82L A78V 
F263L 
A74X, A264X, 
F393X, G402X 
4-ethylanisole none 
3b P-4 A82L A78V 
F263L 
R47X, S142X, 
V184X, G252X, 
E267X 
4-ethyltoluene E267D 
4 P-4 A82L A78V 
F263L E267D 
(P411CHA) 
R47X, Y51X 4-ethyltoluene none 
aSome residues were saturated more than once, in different parent variants. 
 
A74, L181, F263, A264, E267, T327: Distal face of heme, active site residues 
F393, G402: Axial face of heme 
A78, S142, V184, G252: Already mutated in P-4 relative to wild type P450BM3 
R47, Y51: Polar residues that interact with the carboxylate of the native fatty acid substrates 
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Supplementary Table 5. Intermolecular C–H amination data presented in Figure 3. 
Variant Substrate [P411] Yield ee TON 
P-4 4-ethylanisole 1.8 µM 11 ± 1% 14% (S) 310 
P-4 A82L 4-ethylanisole 2.4 µM 51 ± 3% 77% (R) 1000 
P-4 A82L 
A78V 
4-ethylanisole 2.7 µM 66 ± 2% 80% (R) 1200 
P-4 A82L 
A78V F263L 
4-ethylanisole N.A.a 66 ± 2% >99% (R) N.A.a 
P411CHA 4-ethylanisole 3.2 µM 66 ± 3% >99% (R) 1000 
P-4 4-ethyltoluene 1.8 µM 2.0 ± 0.3% N.A. 58 
P-4 A82L 4-ethyltoluene 2.4 µM 11 ± 1% 98% ee (R) 220 
P-4 A82L 
A78V 
4-ethyltoluene 2.7 µM 29 ± 1% >99% ee (R) 530 
P-4 A82L 
A78V F263L 
4-ethyltoluene N.A.a 32 ± 1% >99% ee (R) N.A.a 
P411CHA 4-ethyltoluene 3.2 µM 34 ± 3% >99% ee (R) 530 
P-4 ethylbenzene 1.8 µM 0.50 ± 0.01% N.A. 15 
P-4 A82L ethylbenzene 2.4 µM 2.2 ± 0.1% N.A. 46 
P-4 A82L 
A78V 
ethylbenzene 2.7 µM 6.5 ± 0.4% 92% ee (R) 120 
P-4 A82L 
A78V F263L 
ethylbenzene N.A.a 6.7 ± 0.4% >99% ee (R) N.A.a 
P411CHA ethylbenzene 3.2 µM 15 ± 1% >99% ee (R) 240 
aProtein concentration could not be accurately determined; variant is poorly behaved in carbon 
monoxide-binding assay. 
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Supplementary Table 6. Activity of P411 variants toward C–H amination of indan, tetralin, 1-
bromo-4-ethylbenzene, and 4-propylanisole. Reactions were performed as in Table 2 (2.5 mM 
alkane, 5.0 mM tosyl azide). 
Substrate Product P-4 A82L  
A78V F263L 
P411CHA 
indan N-tosyl-1-aminoindane 72% yield, 90% ee 80% yield, 96% ee 
tetralin N-tosyl-1-aminotetralin 49% yield, 81% ee 76% yield, 95% ee 
1-bromo-4-
ethylbenzene 
N-tosyl-1-(p-
bromophenyl)ethylamine 
13% yield, >99% ee 19% yield, >99% ee 
4-propylanisole N-tosyl-1-(p-
methoxyphenyl)propylamine 
15% yield, >99% ee 16% yield, >99% ee 
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Supplementary Table 7. C–H amination reactions performed under aerobic conditions.a 
 
Variant Conditions Yield 
P-4 A82L A78V anaerobic, full system 66% 
P-4 A82L A78V aerobic, full system 13% 
P-4 A82L A78V aerobic, no glucose oxidase/catalase 7.5% 
P-4 A82L A78V F263L anaerobic, full system 66% 
P-4 A82L A78V F263L aerobic, full system 20% 
P-4 A82L A78V F263L aerobic, no glucose oxidase/catalase 7.6% 
P411CHA anaerobic, full system 66% 
P411CHA aerobic, full system 15% 
P411CHA aerobic, no glucose oxidase/catalase 9.5% 
aReactions performed as in Figure 3 (5 mM 4-ethylanisole, 5 mM tosyl azide). For reactions 
without the glucose oxidase/catalase mixture, 20 µL of M9-N media was added instead. 
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Supplementary Table 8. C–H amination of 4-ethylanisole performed with purified P411 
variants.a 
 
Catalyst Yield, turnovers, ee 
P-4  (5 µM) 2.2% yield, 22 TON, 4% ee (S) 
P-4 A82L (5 µM) 9.7% yield, 97 TON, 80% ee (R) 
P-4 A82L A78V F263L (5 µM) 19% yield, 190 TON, >99% ee (R) 
P411CHA (5 µM) 15% yield, 150 TON, >99% ee (R) 
P411CHA (20 µM) 47% yield, 120 TON, >99% ee (R) 
P-4 A82L A78V F263L (heme domain only, 10 µM)b 1.4% yield, 7 TON 
aReactions performed with 10 mM NADPH, 5 mM 4-ethylanisole, and 5 mM tosyl azide; results 
are the average of duplicate reactions. bPerformed with 5 mM sodium dithionite instead of 
NADPH. 
 
Supplementary Table 9. Reaction mass balances; representative reactions showing amount of 
p-toluenesulfonamide (TsNH2, 5) formed. Reactions are those in Table 2 (performed with 2.5 
mM alkane, 5 mM tosyl azide). 
Table 2 
entry 
Substrate C–H amination 
product  
p-toluene-
sulfonamide 
 
Total of nitrogen-
containing 
products 
1 4-ethylanisole 2.14 mM 2.74 mM 4.88 mM 
2 4-ethyltoluene 1.33 mM 3.51 mM 4.84 mM 
5 ethylbenzene 0.39 mM 4.63 mM 5.01 mM 
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Supplementary Table 10. Enantioselective C–H amination of isochroman with cytochrome 
P411CHA followed by post-reaction racemization.a 
 
Entry Conditions ee 
1 1 hour reaction time 65% 
2 2 hour reaction time 65% 
3 4 hour reaction time 65% 
4 6 hour reaction time 65% 
5 20 hour reaction time 65% 
6 20 hour reaction time, followed by treatment with silica racemic 
aReactions performed as in Table 2, using whole E. coli cells overexpressing P411CHA at OD600 = 
30 (~3 µM enzyme), with 2.5 mM alkane and 5 mM tosyl azide. Identical small scale reactions 
(400 µL) were set up in parallel. After the indicated time, crude reaction mixtures were extracted 
with 1:1 cyclohexane:ethyl acetate, concentrated to dryness, and redissolved in 50% isopropanol 
in cyclohexane. Silica treatment was performed by allowing the crude reaction mixture (in 
cyclohexane/ethyl acetate) to rest on a silica pipette column (approx. 1 hour) followed by elution 
with ethyl acetate. Samples were analyzed by SFC chromatography using Chiralpak AS column 
(35% isopropanol). 
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Representative traces. Racemic standard, N-tosyl-isochroman-1-amine: 
 
 
Supplementary Table 10, Entry 5, with P411CHA (65% ee): 
 
 
Supplementary Table 10, Entry 6, with P411CHA post silica treatment (racemic): 
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Supplementary Table 11. Thermostabilities of cytochrome P411 variants in the evolutionary 
lineage. The T50 is the temperature at which half of the enzyme population has unfolded after a 
10-minute incubation. 
P411 Variant Number of mutations from wild-type T50 (ºC) 
P-4 17 58.3 ± 0.6 
P-4 A82L 18 64.1 ± 0.6 
P-4 A82L A78V F263L 17 62.9 ± 0.2 
P411CHA 18 61.2 ± 0.2 
 
P-4: 
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P-4 A82L: 
 
 
P-4 A82L A78V F263L: 
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P411CHA: 
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Supplementary Figure 1. Unreactive substrates. Substrates for which C–H amination activity 
was not detected (or <1% yield) using cytochrome P411CHA. 
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Characterization of reaction products. Authentic standards corresponding to enzymatic 
reaction products were prepared by tosylation of the corresponding benzylic amine or by racemic 
C–H amination.10 Most products are known compounds, and their spectral data are in agreement 
with reported values.10–15 New compounds were fully characterized. 
 
N-Tosyl-1-(p-methoxyphenyl)ethylamine (Table 2, entry 1): 1H NMR (300 MHz, CDCl3) δ 
7.62 (d, J = 8.3 Hz, 2H), 7.19 (d, J = 8.7 Hz, 2H), 7.05–7.15 (m, 2H), 6.75–6.67 (m, 2H), 4.97 
(d, J = 6.8 Hz, 1H), 4.40 (p, J = 6.8 Hz, 1H), 3.75 (s, 3H), 2.39 (s, 3H), 1.40 (d, J = 6.8 Hz, 3H). 
 
N-Tosyl-1-(p-tolyl)ethylamine (Table 2, entry 2): 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 
8.3 Hz, 2H), 7.20 (d, J = 7.9 Hz, 2H), 7.05–6.95 (m, 4H), 4.65 (d, J = 6.8 Hz, 1H), 4.41 (p, J = 
6.8 Hz, 1H), 2.40 (s, 3H), 2.28 (s, 3H), 1.41 (d, J = 6.8 Hz, 3H). 
 
N-Tosyl-1-(m-tolyl)ethylamine (Table 2, entry 3): 1H NMR (300 MHz, CDCl3) δ 7.60 (d, J = 
8.3 Hz, 2H), 7.18 (d, J = 7.9 Hz, 2H), 7.09 (t, J = 7.6 Hz, 1H), 7.02–6.96 (m, 1H), 6.93–6.87 (m, 
1H), 6.83–6.80 (m, 1H), 4.68 (d, J = 6.9 Hz, 1H), 4.42 (p, J = 6.8 Hz, 1H), 2.39 (s, 3H), 2.22 (s, 
3H), 1.42 (d, J = 6.8 Hz, 3H). 
 
N-Tosyl-1-(o-tolyl)ethylamine (Table 2, entry 4): 1H NMR (300 MHz, CDCl3) δ 7.58 (d, J = 
8.3 Hz, 2H), 7.18–6.98 (m, 6H), 4.78–4.66 (m, 2H), 2.37 (s, 3H), 2.19 (s, 3H), 1.39 (d, J = 6.6 
Hz, 3H). Reactions with P411CHA produce a trace amount of the regioisomer N-tosyl-(2-
ethylphenyl)methanamine (>20:1 r.r. in favor of the secondary benzylic amination product): 1H 
NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 7.9 Hz, 2H), 7.26–7.20 (m, 1H), 
7.17 (d, J = 7.4 Hz, 1H), 7.13–7.09 (m, 2H), 4.38 (t, J = 5.8 Hz, 1H), 4.11 (d, J = 5.9 Hz, 2H), 
2.57 (q, J = 7.6 Hz, 2H), 2.45 (s, 3H), 1.15 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 143.7, 142.9, 136.6, 133.3, 130.0, 129.3, 129.0, 128.6, 127.4, 126.3, 45.0, 25.2, 21.7, 15.3; IR 
(film) 3278, 2966, 1451, 1421, 1325, 1158, 1093, 1048, 814, 662 cm-1; HRMS (FAB+) exact 
mass calculated for C16H20NO2S+ requires m/z 290.1215, found 290.1221. 
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N-Tosyl-1-phenylethylamine (Table 2, entry 5): 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 8.3 
Hz, 2H), 7.24–7.14 (m, 5H), 7.13–7.06 (m, 2H), 4.94 (d, J = 7.0 Hz, 1H), 4.46 (p, J = 6.9 Hz, 
1H), 2.38 (s, 3H), 1.42 (d, J = 6.9 Hz, 3H). 
 
N-Tosyl-1-(p-bromophenyl)ethylamine (Table 2, entry 6): 1H NMR (400 MHz, CDCl3) δ 7.57 
(d, J = 8.3 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 7.8 Hz, 2H), 6.97 (d, J = 8.3 Hz, 2H), 
4.78 (d, J = 6.8 Hz, 1H), 4.43 (p, J = 6.9 Hz, 1H), 2.40 (s, 3H), 1.39 (d, J = 6.9 Hz, 3H). 
 
N-Tosyl-1-(p-chlorophenyl)ethylamine (Table 2, entry 7): 1H NMR (300 MHz, CDCl3) δ 7.57 
(d, J = 8.3 Hz, 2H), 7.22–7.12 (m, 4H), 7.05–7.00 (m, 2H), 4.70 (d, J = 6.7 Hz, 1H), 4.45 (p, J = 
6.9 Hz, 1H), 2.40 (s, 3H), 1.39 (d, J = 6.8 Hz, 3H). 
 
N-Tosyl-1-(p-fluorophenyl)ethylamine (Table 2, entry 8): 1H NMR (300 MHz, CDCl3) δ 7.59 
(d, J = 8.3 Hz, 2H), 7.24–7.14 (m, 2H), 7.13–7.03 (m, 2H), 6.94–6.80 (m, 2H), 4.77 (d, J = 6.7 
Hz, 1H), 4.46 (p, J = 6.8 Hz, 1H), 2.39 (s, 3H), 1.40 (d, J = 6.9 Hz, 3H). 
 
N-Tosyl-1-aminoindane (Table 2, entry 9): 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 8.3 Hz, 
2H), 7.38–7.32 (m, 2H), 7.25–7.12 (m, 3H), 7.08 (d, J = 7.4 Hz, 1H), 4.84 (q, J = 7.8 Hz, 1H), 
4.60 (d, J = 9.0 Hz, 1H), 2.90 (ddd, J = 16.0, 8.7, 3.7 Hz, 1H), 2.75 (dt, J = 16.3, 8.2 Hz, 1H), 
2.46 (s, 3H), 2.40–2.29 (m, 1H), 1.82–1.69 (m, 1H). 
 
N-Tosyl-1-aminotetralin (Table 2, entry 10): 1H NMR (300 MHz, CDCl3) δ 7.83 (d, J = 8.3 
Hz, 2H), 7.39–7.31 (m, 2H), 7.20–6.90 (m, 4H), 4.59 (d, J = 7.7 Hz, 1H), 4.45 (dt, J = 7.9, 4.6 
Hz, 1H), 2.85–2.57 (m, 2H), 2.47 (s, 3H), 1.95–1.62 (m, 4H). 
 
N-Tosyl-3-amino-2,3-dihydrobenzofuran (Table 2, entry 11): 1H NMR (400 MHz, CDCl3) δ 
7.81 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 7.9 Hz, 2H), 7.23–7.17 (m, 1H), 6.94–6.88 (m, 1H), 6.86–
6.78 (m, 2H), 5.05 (ddd, J = 8.1, 8.1, 4.1 Hz, 1H), 4.77 (d, J = 8.5 Hz, 1H), 4.49 (dd, J = 10.3, 
7.9 Hz, 1H), 4.28 (dd, J = 10.3, 4.1 Hz, 1H), 2.48 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 160.0, 144.1, 137.8, 130.9, 130.2, 127.3, 125.3, 125.0, 121.4, 110.7, 77.4, 55.6, 21.8; IR (film) 
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3284, 2921, 1598, 1482, 1330, 1155, 1082, 970, 750, 667 cm-1; HRMS (FAB+) exact mass 
calculated for C15H16NO3S+ requires m/z 290.0851, found 290.0855. 
 
N-Tosyl-1-(2-naphthyl)ethylamine (Table 2, entry 12): 1H NMR (400 MHz, CDCl3) δ 7.78–
7.72 (m, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 8.3 Hz, 2H), 7.48–7.41 (m, 3H), 7.20 (dd, J = 
8.5, 1.8 Hz, 1H), 7.06–7.01 (m, 2H), 4.90 (d, J = 7.0 Hz, 1H), 4.64 (p, J = 6.9 Hz, 1H), 2.25 (s, 
3H), 1.52 (d, J = 6.8 Hz, 3H). 
 
N-Tosyl-1-(1-naphthyl)ethylamine (Table 2, entry 13): 1H NMR (300 MHz, CDCl3) δ 7.92–
7.77 (m, 2H), 7.69 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 8.3 Hz, 2H), 7.50–7.26 (m, 4H), 7.07 (d, J = 
7.7 Hz, 2H), 5.28 (p, J = 6.8 Hz, 1H), 4.94 (d, J = 6.7 Hz, 1H), 2.33 (s, 3H), 1.60 (d, J = 6.8 Hz, 
3H). 
 
N-Tosyl-1-(p-methoxyphenyl)propylamine (Table 2, entry 14): 1H NMR (400 MHz, CDCl3) δ 
7.54 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 7.8 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H), 6.68 (d, J = 8.7 Hz, 
2H), 4.77 (d, J = 7.0 Hz, 1H), 4.13 (q, J = 7.1 Hz, 1H), 3.75 (s, 3H), 2.37 (s, 3H), 1.88–1.62 (m, 
2H), 0.76 (t, J = 7.4 Hz, 3H). 
 
N-Tosyl-4-methoxybenzylamine (Table 2, entry 15): 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J 
= 8.3 Hz, 2H), 7.34–7.29 (m, 2H), 7.11 (d, J = 8.9 Hz, 2H), 6.80 (d, J = 8.8 Hz, 2H), 4.52 (t, J = 
6.1 Hz, 1H), 4.05 (d, J = 6.1 Hz, 2H), 3.78 (s, 3H), 2.44 (s, 3H). 
 
N-Tosyl-1,3-dihydroisobenzofuran-1-amine (Table 2, entry 16): 1H NMR (400 MHz, CDCl3) 
δ 7.86 (d, J = 8.4 Hz, 2H), 7.38–7.28 (m, 5H), 7.24–7.18 (m, 1H), 6.55 (dd, J = 10.2, 2.1 Hz, 
1H), 5.21 (d, J = 10.2 Hz, 1H), 5.00 (dd, J = 12.6, 2.6 Hz, 1H), 4.91 (d, J = 12.6 Hz, 1H), 2.45 (s, 
3H). 
 
N-Tosyl-isochroman-1-amine (Table 2, entry 17): 1H NMR (300 MHz, CDCl3) δ 7.86 (d, J = 
8.4 Hz, 2H), 7.35–7.28 (m, 2H), 7.25–7.18 (m, 3H), 7.12–7.05 (m, 1H), 6.11 (d, J = 8.6 Hz, 1H), 
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5.37 (d, J = 8.5 Hz, 1H), 3.74–3.58 (m, 2H), 2.85 (ddd, J = 16.5, 9.2, 6.0 Hz, 1H), 2.61 (dt, J = 
16.6, 3.9 Hz, 1H), 2.44 (s, 3H). 
 
HPLC Calibration: Calibration curves with an internal standard were created for quantitative 
HPLC analysis of reaction products. The identity of the products was additionally confirmed by 
HPLC co-injections of reaction mixtures with chemically synthesized authentic products, or by 
NMR analysis of products isolated from reactions performed on preparative scale. 
 
N-Tosyl-1-(p-methoxyphenyl)ethylamine (4), with 1.25 mM 1,3,5-trimethoxybenzene as internal 
standard, at 230 nm. 
 
 
 
 
 
 
 
 
y = 0.5505x 
R² = 0.99919 
0 
1 
2 
3 
4 
5 
6 
0 2 4 6 8 10 
m
M
 a
na
ly
te
 
HPLC ratio (analyte/IS) 
MeO
Me
NHTs
 		 26 
N-Tosyl-1-(p-tolyl)ethylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal standard, at 
230 nm. 
 
 
N-Tosyl-1-(m-tolyl)ethylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal standard, at 
230 nm. 
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N-Tosyl-1-(o-tolyl)ethylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal standard, at 
230 nm. 
 
 
N-Tosyl-1-phenylethylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal standard, at 
230 nm. 
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N-Tosyl-1-(p-bromophenyl)ethylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal 
standard, at 230 nm. 
	
 
N-Tosyl-1-(p-chlorophenyl)ethylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal 
standard, at 230 nm. 
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N-Tosyl-1-(p-fluorophenyl)ethylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal 
standard, at 230 nm. 
	
 
N-Tosyl-1-aminoindane, with 1.25 mM 1,3,5-trimethoxybenzene as internal standard, at 230 nm. 
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N-Tosyl-1-aminotetralin, with 1.25 mM 1,3,5-trimethoxybenzene as internal standard, at 230 nm. 
 
 
N-Tosyl-1-(2-naphthyl)ethylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal standard, 
at 230 nm. 
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N-Tosyl-1-(1-naphthyl)ethylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal standard, 
at 230 nm. 
	
 
N-Tosyl-1-(p-methoxyphenyl)propylamine, with 1.25 mM 1,3,5-trimethoxybenzene as internal 
standard, at 230 nm. 
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N-Tosyl-4-methoxybenzylamine, with 1.0 mM methyl phenylacetate as internal standard, at 210 
nm. 
 
 
p-Toluenesulfonamide, with 1.25 mM 1,3,5-trimethoxybenzene as internal standard, at 230 nm. 
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Determination of enantioselectivity. 
For the determination of enantioselectivity, reaction mixtures were extracted with cyclohexane, 
or purified compounds were dissolved in 20% isopropanol in hexanes, and samples were 
analyzed by chiral SFC. Representative traces are shown below. 
 
Assignment of absolute stereochemistry. Absolute stereochemistry was assigned by chemical 
synthesis of (R)-N-tosyl-1-(p-methoxyphenyl)ethylamine, (S)-N-tosyl-1-(p-tolyl)ethylamine, and 
(R)-N-tosyl-1-(1-naphthyl)ethylamine. Comparison to the enzymatic reactions reveals the 
enzymatic products to be the R enantiomer. Other benzylic amine products were assigned by 
analogy. 
 
N-Tosyl-1-(p-methoxyphenyl)ethylamine (Table 2, entry 1). Measured by SFC 
chromatography using Chiralpak AS (25% isopropanol). Racemic standard:  
 
R-enantiomer, chemically prepared: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
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N-Tosyl-1-(p-tolyl)ethylamine (Table 2, entry 2). Measured by SFC chromatography using 
Chiralpak AS (25% isopropanol). Racemic standard: 
 
S-enantiomer, chemically prepared: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
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N-Tosyl-1-(m-tolyl)ethylamine (Table 2, entry 3). Measured by SFC chromatography using 
Chiralpak AS (25% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
 
 
 
N-Tosyl-1-(o-tolyl)ethylamine (Table 2, entry 4). Measured by SFC chromatography using 
Chiralpak AS (30% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (87% ee): 
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N-Tosyl-1-phenylethylamine (Table 2, entry 5). Measured by SFC chromatography using 
Chiralpak AS (25% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
 
 
 
N-Tosyl-1-(p-bromophenyl)ethylamine (Table 2, entry 6). Measured by SFC chromatography 
using Chiralpak AS (30% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
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N-Tosyl-1-(p-chlorophenyl)ethylamine (Table 2, entry 7). Measured by SFC chromatography 
using Chiralpak AS (25% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
 
 
 
N-Tosyl-1-(p-fluorophenyl)ethylamine (Table 2, entry 8). Measured by SFC chromatography 
using Chiralpak AS (25% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
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N-Tosyl-1-aminoindane (Table 2, entry 9). Measured by SFC chromatography using Chiralpak 
AS (35% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (96% ee): 
 
 
 
N-Tosyl-1-aminotetralin (Table 2, entry 10). Measured by SFC chromatography using 
Chiralpak AS (40% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (95% ee): 
 
 
 
 
 		 39 
N-Tosyl-3-amino-2,3-dihydrobenzofuran (Table 2, entry 11). Measured by SFC 
chromatography using Chiralpak AS (30% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (92% ee): 
 
 
 
N-Tosyl-1-(2-naphthyl)ethylamine (Table 2, entry 12). Measured by SFC chromatography 
using Chiralpak AS (40% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
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N-Tosyl-1-(1-naphthyl)ethylamine (Table 2, entry 13). Measured by SFC chromatography 
using Chiralpak AS (40% isopropanol). Racemic standard: 
 
R-enantiomer, chemically prepared: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
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N-Tosyl-1-(p-methoxyphenyl)propylamine (Table 2, entry 14). Measured by SFC 
chromatography using Chiralpak AS (25% isopropanol). Racemic standard: 
 
Enzymatic reaction, with P411CHA (>99% ee): 
 
 
Preparative scale reactions. E. coli BL21 E. cloni cells transformed with the plasmid encoding 
P411CHA were grown overnight in 25 mL LBamp (37 ºC, 250 rpm). Hyperbroth medium (470 mL, 
0.1 mg/mL
 
ampicillin) in a 1-L flask was inoculated with 19 mL of the preculture and incubated 
at 37 ºC and 230 rpm for 2.5 h (to OD600 ca. 1.8). Cultures were then cooled on ice (30 min) and 
induced with 0.5 mM IPTG and 1.0 mM 5-aminolevulinic acid (final concentrations). Expression 
was conducted at room temperature (23 ºC) at 130 rpm for 16–18 h (to OD600 ca. 7.0). Cultures 
were then centrifuged (2,600 x g, 10 min, 4 ºC) and the pellets resuspended to OD600 = 30 in M9-
N. Aliquots of the cell suspension (4 mL) were used to determine the P411 expression level after 
lysis by sonication. The cells (80 mL) were then combined with glucose (10 mL, 250 mM in M9-
N) in a 250-mL Erlenmeyer flask and degassed by sparging with argon for at least 40 minutes. 
The reaction flask was then transferred into an anaerobic chamber. To the flask were added the 
oxygen depletion system (5 mL, 14,000 U/mL catalase and 1,000 U/mL glucose oxidase in 0.1 
M KPi, pH 8.0) followed by alkane (2.5 mL, 100 mM in DMSO) and tosyl azide (2.5 mL, 200 
mM in DMSO). Final concentrations were typically 2.5 mM alkane, 5.0 mM tosyl azide, and 25 
mM glucose; final reaction volume was 100 mL. The flask was sealed with parafilm, removed 
from the anaerobic chamber, and shaken at room temperature and 130 rpm for 20 h. The reaction 
was quenched by adding acetonitrile (50 mL) and then centrifuged (4,000 x g, 10 min). The 
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supernatant was concentrated and extracted with EtOAc (3 x 25 mL). The organic layers were 
washed with brine (20 mL), dried over MgSO4, filtered, concentrated, and purified by 
chromatography. 
 
N-Tosyl-1-(p-methoxyphenyl)ethylamine. The reaction was performed under two different 
conditions. To optimize yield, the reaction was performed on 0.25-mmol scale with 2.5 mM 4-
ethylanisole, 5.0 mM tosyl azide, and 3.18 µM P411CHA. The product was purified by silica gel 
chromatography (5 to 30% EtOAc/hexanes). Isolated 59.5 mg (78% yield, 610 TON, >99% ee). 
To optimize turnovers, the reaction was performed on 1.0-mmol scale with 10 mM 4-
ethylanisole, 10 mM tosyl azide, and 2.80 µM P411CHA. The product was purified by silica gel 
chromatography (20 to 30% EtOAc/hexanes). Isolated 103.3 mg (34% yield, 1,200 TTN, >99% 
ee). 
 
N-Tosyl-3-amino-2,3-dihydrobenzofuran (Table 2, entry 11). The reaction was performed on 
0.25-mmol scale with 2.5 mM 2,3-dihydrobenzofuran, 5.0 mM tosyl azide, and 2.98 µM 
P411CHA. The product was purified by C18 chromatography (5 to 100% MeCN/water). Isolated 
15.1 mg (21% yield, 180 TON, 92% ee). 
 
N-Tosyl-1,3-dihydroisobenzofuran-1-amine (Table 2, entry 16). The reaction was performed 
on 0.25-mmol scale with 2.5 mM o-xylylene oxide, 5.0 mM tosyl azide, and 2.86 µM P411CHA. 
The product was purified by preparative HPLC (50 to 100% MeCN/water). Isolated 50.7 mg 
(70% yield, 610 TON). 
 
N-Tosyl-isochroman-1-amine (Table 2, entry 17). The reaction was performed on 0.25-mmol 
scale with 2.5 mM isochroman, 5.0 mM tosyl azide, and 2.73 µM P411CHA. The product was 
purified by silica gel chromatography (5 to 30% EtOAc/hexanes). Isolated 60.6 mg (80% yield, 
730 TON). 
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Tosyl group removal. Tosyl group removal was performed by the method of Ankner and 
Hilmersson.16 
 
Enzymatically produced tosylamide 4 (30.5 mg, 0.1 mmol, >99% ee) in dry THF (1 mL) was 
added to a 0.1 M solution of SmI2 in THF (20 mL, 2.0 mmol) at room temperature under argon. 
Water (108 µL, 6.0 mmol, degassed for 10 min with argon) and pyrrolidine (334 µL, 4.0 mmol, 
degassed for 10 min with argon) were then added. The solution was allowed to stir at room 
temperature under argon for 1.5 hours. The resulting reaction mixture was diluted with diethyl 
ether (20 mL) and quenched with a solution of potassium sodium tartrate and potassium 
carbonate (20 mL, 10% w/v each). The aqueous phase was extracted with three portions of 
diethyl ether (3 × 20 mL). The combined organics were pooled and evaporated to yield the crude 
amine. The crude amine was taken up in aqueous 10% HCl solution (5 mL) and washed with 
diethyl ether (4 × 3 mL). The aqueous layer was basified with 10% NaOH solution (5 mL) to pH 
14 and extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried 
over Na2SO4. Concentration gave (R)-1-(4-methoxyphenyl)ethanamine (9.2 mg, 61% yield) as 
an oil with spectral data in agreement with reported values.17 The ee was determined to be >99% 
using an Agilent 7820A GC equipped with a Cyclosil-B chiral column (30 m × 0.320 mm, 0.25 
µm film); method: 90–98 °C at 0.1 °C/min, 98–240 °C at 15 °C/min, 240 °C hold 5 min. 
(R)-1-(4-methoxyphenyl)ethanamine: 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 8.5 Hz, 2H), 
6.87 (d, J = 8.7 Hz, 2H), 4.08 (q, J = 6.6 Hz, 1H), 3.80 (s, 3H), 1.59 (br s, 2H), 1.36 (d, J = 6.6 
Hz, 3H). 
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Representative traces. Racemic standard, 1-(4-methoxyphenyl)ethanamine:  
 
 
(R)-1-(4-methoxyphenyl)ethanamine from tosyl group removal of enzymatically produced 4:  
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Determination of initial rates. Portions of phosphate buffer (260 µL 0.1 M KPi, pH 8.0) and 
NADPH (40 µL, 100 mM), or multiples thereof, were combined in a 6-mL crimp vial and 
degassed by sparging with argon for at least 30 minutes. Separately, glucose solution (250 mM 
in 0.1 M KPi, buffer pH 8.0) was also degassed in the same manner. In preparation, 2-mL crimp 
vials were each charged with a stir bar and the oxygen depletion system (20 µL of a stock 
solution containing 14,000 U/mL catalase and 1,000 U/mL glucose oxidase in 0.1 M KPi, pH 
8.0). After degassing was complete, all degassed solutions, prepared 2-mL crimp vials, and 
purified protein (100 µM in 0.1 M KPi pH 8.0), kept on ice, were brought into the anaerobic 
chamber. Glucose solution (40 µL), reaction solution (300 µL), and purified protein (20 µL of 
100 µM stock solution) were added to each 2-mL vial; the vials were placed on a stir plate and 
allowed to stir for 5 minutes. Reaction vials were then charged with alkane (10 µL, 200 mM in 
DMSO) and tosyl azide (10 µL, 200 mM in DMSO). Final concentrations were 5 mM alkane, 5 
mM tosyl azide, 10 mM NADPH, 25 mM glucose, and 5 µM P411; final reaction volumes were 
400 µL. Reactions were set up in duplicate and products quantified at 1-minute intervals by 
quenching with acetonitrile containing internal standard (410 µL). This mixture was then 
removed from the anaerobic chamber, transferred to a microcentrifuge tube, and centrifuged at 
20,000 x g for 10 minutes. The supernatant was transferred to a vial and analyzed by HPLC. 
Rates of C–H amination and azide reduction were measured from the same reactions. 
 
Supplementary Table 12. Initial rates of intermolecular C–H amination and azide reduction.a 
Variant TOF 4 TOF TsNH2 (5) 
P-4 0.73 min–1 29.1 min–1 
P-4 A82L 3.0 min–1 13.6 min–1 
P-4 A82L A78V F263L 7.3 min–1 12.2 min–1 
P411CHA 6.4 min–1 23.7 min–1 
aVariant P-4 A82L A78V F263L outperforms P411CHA in vitro, demonstrating differences in 
enzyme activities under whole cell versus in vitro conditions. 
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Supplementary Figure 2. Initial rates of intermolecular C–H amination of 4-ethylanisole. 
 
Supplementary Figure 3. Initial rates of azide reduction in the C–H amination of 4-
ethylanisole.
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Kinetic isotope effect. 
4-Ethylanisole-d2 was prepared according the procedure of Kurita et al.18 to 97% deuterium 
incorporation at the benzylic position. Independent rate experiments with P411CHA show a KIE 
(kH/kD) = 1.6; rate experiments with P-4 A82L A78V F263L show a KIE = 1.4. 
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Gene sequence of cytochrome P411CHA. 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAA
ACACAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATT
CGAGGCGCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGAT
GAATCACGCTTTGATAAAAACTTAAGTCAAGCGCTGAAATTTGTGCGTGATTTTCTTGGAGACG
GGTTAGCCACAAGCTGGACGCATGAAAAAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAG
CTTTAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTT
CAAAAGTGGGAGCGTCTAAATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGTTTAA
CGCTTGATACAATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCC
TCATCCATTTATTATAAGTATGGTCCGTGCACTGGATGAAGTAATGAACAAGCTGCAGCGAGCA
AATCCAGACGACCCAGCTTATGATGAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGA
ACGACCTAGTAGATAAAATTATTGCAGATCGCAAAGCAAGGGGTGAACAAAGCGATGATTTATT
AACGCAGATGCTAAACGGAAAAGATCCAGAAACGGGTGAGCCGCTTGATGACGGGAACATTCGC
TATCAAATTATTACATTCTTACTGGCGGGACACGATGGTACAAGTGGTCTTTTATCATTTGCGC
TGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGTAGCAGAAGAAGCAGCACGAGTTCT
AGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAAC
GAAGCGCTGCGCTTATGGCCAACTGTGCCTGCGTTTTCCCTATATGCAAAAGAAGATACGGTGC
TTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGATTCCTCAGCTTCACCG
TGATAAAACAGTTTGGGGAGACGATGTGGAGGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGT
GCGATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGTCTATCGGTCAGCAGT
TCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTGAAGATCA
TACAAACTACGAGCTCGATATTAAAGAAACTTTAAGCTTAAAACCTAAAGGCTTTGTGGTAAAA
GCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAAAA
AAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATAT
GGGTACCGCTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCG
CAGGTCGCAACGCTTGATTCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAA
CGGCGTCTTATAACGGTCATCCGCCTGATAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGC
GTCTGCTGATGAAGTAAAAGGCGTTCGCTACTCCGTATTTGGATGCGGCGATAAAAACTGGGCT
ACTACGTATCAAAAAGTGCCTGCTTTTATCGATGAAACGCTTGCCGCTAAAGGGGCAGAAAACA
TCGCTGACCGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATGGCGTGA
ACATATGTGGAGTGACGTAGCAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAA
TCTACTCTTTCACTTCAATTTGTCGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTG
CGTTTTCAACGAACGTCGTAGCAAGCAAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCG
ACATCTTGAAATTGAACTTCCAAAAGAAGCTTCTTATCAAGAAGGAGATCATTTAGGTGTTATT
CCTCGCAACTATGAAGGAATAGTAAACCGTGTAACAGCAAGGTTCGGCCTAGATGCATCACAGC
AAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCTCATTTGCCACTCGCTAAAACAGTATCCGT
AGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTGTTACGCGCACGCAGCTTCGCGCAATG
GCTGCTAAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGAAGCCTTGCTTGAAAAGCAAGCCT
ACAAAGAACAAGTGCTGGCAAAACGTTTAACAATGCTTGAACTGCTTGAAAAATACCCGGCGTG
TGAAATGAAATTCAGCGAATTTATCGCCCTTCTGCCAAGCATACGCCCGCGCTATTACTCGATT
TCTTCATCACCTCGTGTCGATGAAAAACAAGCAAGCATCACGGTCAGCGTTGTCTCAGGAGAAG
CGTGGAGCGGATATGGAGAATATAAAGGAATTGCGTCGAACTATCTTGCCGAGCTGCAAGAAGG
AGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAATTTACGCTGCCAAAAGACCCTGAA
ACGCCGCTTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGGCTTTGTGCAGGCGC
GCAAACAGCTAAAAGAACAAGGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCCGTTC
ACCTCATGAAGACTATCTGTATCAAGAAGAGCTTGAAAACGCCCAAAGCGAAGGCATCATTACG
CTTCATACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACGTTCAGCACGTAATGGAAC
 		 49 
AAGACGGCAAGAAATTGATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGAGACGG
AAGCCAAATGGCACCTGCCGTTGAAGCAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTG
AGTGAAGCAGACGCTCGCTTATGGCTGCAGCAGCTAGAAGAAAAAGGCCGATACGCAAAAGACG
TGTGGGCTGGG 
 
Amino acid sequence of cytochrome P411CHA. 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACD
ESRFDKNLSQALKFVRDFLGDGLATSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLV
QKWERLNADEHIEVSEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRALDEVMNKLQRA
NPDDPAYDENKRQFQEDIKVMNDLVDKIIADRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIR
YQIITFLLAGHDGTSGLLSFALYFLVKNPHVLQKVAEEAARVLVDPVPSYKQVKQLKYVGMVLN
EALRLWPTVPAFSLYAKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGDDVEEFRPERFENPS
AIPQHAFKPFGNGQRASIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETLSLKPKGFVVK
AKSKKIPLGGIPSPSTEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAP
QVATLDSHAGNLPREGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWA
TTYQKVPAFIDETLAAKGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNK
STLSLQFVDSAADMPLAKMHGAFSTNVVASKELQQPGSARSTRHLEIELPKEASYQEGDHLGVI
PRNYEGIVNRVTARFGLDASQQIRLEAEEEKLAHLPLAKTVSVEELLQYVELQDPVTRTQLRAM
AAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLELLEKYPACEMKFSEFIALLPSIRPRYYSI
SSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAELQEGDTITCFISTPQSEFTLPKDPE
TPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIIT
LHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQMAPAVEATLMKSYADVHQV
SEADARLWLQQLEEKGRYAKDVWAG 
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Crystallization, X-ray data collection, and protein structure determination of P-4 A82L 
A78V F263L heme domain. The construct employed for crystallization is the heme domain of 
variant P-4 A82L A78V F263L (residues 1 to 463 of the holoprotein, followed by an XhoI site 
and a C-terminal His-tag). The amino acid sequence is: 
 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACD
ESRFDKNLSQALKFVRDFLGDGLATSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLV
QKWERLNADEHIEVSEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRALDEVMNKLQRA
NPDDPAYDENKRQFQEDIKVMNDLVDKIIADRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIR
YQIITFLLAGHEGTSGLLSFALYFLVKNPHVLQKVAEEAARVLVDPVPSYKQVKQLKYVGMVLN
EALRLWPTVPAFSLYAKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGDDVEEFRPERFENPS
AIPQHAFKPFGNGQRASIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETLSLKPKGFVVK
AKSKKIPLGGIPSPSTLEHHHHHH 
 
 The heme domain of variant P-4 A82L A78V F263L was crystalized by vapor diffusion. 
A 1:1 mixture of protein stock (22 mg/mL protein in 25 mM tris-HCl, 25 mM NaCl, pH 7.5 
buffer) and mother liquor were combined in 24-well sitting drop plates (Hampton Research). The 
crystals were grown at room temperature over a span of 4–10 days. Crystals formed in 0.1 M bis-
tris pH 4.0–5.0, 13% PEG 3350, 0.2 M NaHCOO. Data was collected on a crystal that formed 
under the following conditions: 0.1 M Bis-tris pH 5.0, 13% PEG 3350, 0.2 M NaHCOO. 
Crystals were cryo-protected by immersion into well solution with 25% glycerol before being 
flash-frozen in liquid N2. Diffraction data were collected on the Stanford Synchrotron Radiation 
Laboratory Beamline 12-2. Data was processed using XDS19 in the space group P21212 and 
scaled using AIMLESS20 to 1.70-Å resolution. 
 The structure of P-4 A82L A78V F263L was solved by molecular replacement using 
PHASER, as implemented in CCP4, using the P411BM3-CIS T438S I263F structure (PDB ID: 
4WG2) as the search model. Model building was performed in Coot and restrained refinement 
performed using Refmac5.21,22  TLS operators were included in the last round of refinement.23 
Model quality was assessed with the MolProbity online server.24 Crystallographic and model 
statistics are described in Supplementay Table 13. 
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Supplementary Table 13. X-ray crystallography analysis of cytochrome 
P411BM3 P-4 A82L A78V F263L. 
 
   
Data collection   
Protein Cytochrome P411BM3 P-4 A82L A78V F263L 
PDB ID 5UCW 
Beamline SSRL 12.2a 
Space group P21212 
Cell dimensions  
    a, b, c (Å) 123.9, 127.0, 62.6 
    α, β, γ (°) 90.0, 90.0, 90.0 
  
Wavelength 0.9795 
Resolution (Å) (last bin A) 
 
 
 
40.0 – 1.70  
Last bin (Å) 1.73 – 1.70 
Rmeas (%)b 5.5 (262.2) 
Rpim (%)b 1.5 (69.8) 
CC1/2 b 1.00 (0.593) 
< I / σI >b 23.9 (1.3) 
Completeness (%)b 99.8 (100.0) 
No. of observations 1,462,616  
No. of unique reflectionsb 108,841 (5,345) 
Redundancyb 13.4 (13.8) 
  
Refinement  
Resolution (Å) 40.0 – 1.70 
Final bin (Å) 1.744 – 1.700 
No. of reflections 103,324 
No. of reflections test set 5,400 (5.0%) 
Rwork / Rfreeb 18.9 / 22.3 (34.4 / 33.1) 
Total no. atoms (non-hydrogen) 7,709 
Average B-factor (Å2) 42.2 
RMSD  
    Bond lengths (Å)  0.012 
    Bond angles (°) 1.44 
  
Ramachandran plotc  
    Favored (%) 97.3 
    Additionally allowed (%) 2.7 
    Outliers (%) 0.0 
  
MolProbity  
    Clashscorec 2.76 (99th percentile) 
    Molprobity scorec 1.29 (97th percentile) 
   
aSSRL, Stanford Synchotron Radiation Lightsource. bHighest-resolution shell is shown in parentheses. cAs 
determined by MolProbity. 
Rwork is ||Fo – Fc|| / Fo, where Fo is an observed amplitude and Fc a calculated amplitude; Rfree is the same statistic 
calculated over a 5.0% subset of the data that has not been included during refinement. 
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Structure of P-4 A82L A78V F263L. 
The structure of P-4 A82L A78V F263L adopts the P450 closed conformation, aligning well 
with the two previously obtained cytochrome P411 structures (PDB IDs 4WG2 and 4H23) as 
well as with P450BM3 wild type in complex with N-palmitoylglycine (1JPZ).25 
 
 
Supplementary Figure 4. Heme domain protein alignments of cytochrome P411BM3 P-4 A82L 
A78V F263L with wild type P450BM3 and other P411BM3 structures. Top panels show alignments 
of P411BM3 P-4 A82L A78V F263L (cyan) with open (substrate free) form of wild type P450BM3 
(tan, PDB 2IJ2) and closed (substrate bound) form of wild-type P450BM3 (magenta, PDB 1JPZ). 
Large movements of the I, F, and G helices are observed when comparing P-4 A82L A78V 
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F263L with the open form of wild-type P450BM3 (arrows); the position of these helices align 
more closely with the closed form of wild type P450BM3. Bottom panels show alignments of 
P411BM3 P-4 A82L A78V F263L (cyan) with previously obtained P411BM3 structures, P411BM3-
CIS (orange, PDB 4H23) and P-I263F (green, PDB 4WG2). No significant structural changes are 
observed. Protein alignments were carried about using the align tool of PyMOL (PyMOL 
Molecular Graphics System, Version 1.3, Schrodinger LLC). 
 
The structure of P-4 A82L A78V F263L was compared closely to that of P-I263F (4WG2), as 
differences between these structures may reflect features that account for the emergence of 
intermolecular C–H amination activity: these two variants differ by only six mutations, yet P-4 
A82L A78V F263L is a competent intermolecular amination catalyst while P-I263F gives only 
trace product. Comparisons between structures were made by performing pairwise alignments 
using secondary structure matching (SSM) in Coot or aligning backbone atoms in PyMOL (zero 
cycles). Globally, the largest differences in the position of protein backbone atoms are observed 
between the F and G helices and the F/G and G/H loops, which are known to be the most 
variable regions of P450s (Supplementary Fig. 5).26 Volumes of the heme distal pocket were 
estimated by the CASTp server using a 1.4-Å probe.27 Estimated volumes for P-4 A82L A78V 
F263L were 1489 and 1411 Å3 for the two chains; estimated volumes for P-I263F (4WG2) were 
1422, 1655, and 1737 Å3 for the three chains. 
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Supplementary Figure 5. Representative plots of r.m.s. difference between the backbone atoms 
of P-4 A82L A78V F263L and P-I263F (PDB 4WG2). Blue: comparison of molecule A in P-4 
A82L A78V F263L and molecule A in P-I263F. Yellow: comparison of molecule B of P-4 A82L 
A78V F263L and molecule C of P-I263F.	
 
Local differences within the distal heme pocket were also observed between P-4 A82L A78V 
F263L and P-I263F. Notably, the mutation A268G of P-4 A82L A78V F263L displays a ~0.8-Å 
movement of C(α) closer to C2 of the heme cofactor; simple mutation of G268 back to alanine in 
P-4 A82L A78V F263L, using Coot, shows steric clash of the methyl side chain with the heme, 
suggesting the protein would not be able to adopt this conformation with alanine at this position. 
The backbone of the B' helix (site of the mutations A82L and A78V) shifts by 0.6 to 0.9 Å 
toward the distal heme face. In general, the backbones of the I-helices between the two structures 
align well, with the exception of the backbone nitrogen of A264, which shifts by 0.7 Å from its 
position in P-I263F to accommodate the F263L mutation in P-4 A82L A78V F263L. Other 
notable residues in the P-4 A82L A78V F263L structure include P329, which has changed to 
endo conformation from exo in P-I263F, and L437, which has significantly changed torsion 
angles. 
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Docking simulations. 
Docking simulations were performed using Autodock Vina and the crystal structure of P-4 A82L 
A78V F263L.28 BioLuminate (Schrödinger) was used to draw ligands, and AutoDockTools was 
used to generate PDBQT files. To simulate the orientation of the nitrenoid intermediate, a ligand 
was created having the nitrogen atom linked to the iron of the heme cofactor; the Fe–N distance 
was set to 1.8 Å.29 Docking this ligand into the cofactor-free structure gave an output having the 
heme approximately in the same orientation as that observed in the crystal structure 
(Supplementary Fig. 6). The arene and p-methyl group of the reagent pack against the I helix, 
making interactions with F263 (3.7 Å), A264 (3.9 Å), and E267 (3.5 Å). Other residues at close 
distances to the ligand are L181 on the F helix, and A87, V328, and S438 on active-site loops.  
 
 
 
 
 
264	
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Supplementary Figure 6. 
Docking of the metal 
nitrenoid/heme complex 
into the active site of P411 
variant P-4 A82L A78V 
F263L. The docked ligand is 
shown in white; the 
orientation of the heme in 
the crystal structure is 
shown in magenta. 
Distances of closest contact 
between the ligand and 
active site residues are 
shown as black dashes.		
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 To simulate the conformation of the nitrenoid and alkane reagents during the C–H 
amination event, we attempted to dock the product of amination. Docking of the product (R)-4 
into the structure of the cofactor-bound enzyme, however, did not reveal binding modes relevant 
to the bond-forming step (i.e., Fe–N distances of all outputs were >6.5 Å). Therefore, the product 
(R)-4 was linked to the heme via nitrogen and this ligand docked into the cofactor-free structure 
(as described above for the nitrenoid model). The Fe–N distance was set to 2.1 Å, as observed in 
imidazole-bound P450 structures.30 Only outputs showing the correct orientation of the heme 
were considered. Various simulations, with the ligand docked into either chain of the protein, 
with different configurations at nitrogen, or with alternative substrates, repeatedly identified two 
general binding modes for the product. In one mode, the sulfonamide occupies the site near the I 
helix observed in the nitrenoid model (above), while the anisole ring is oriented toward the B' 
helix, specifically residue L75 (Supplementary Fig. 7). 
 In the other binding mode, the positions of the two arenes are roughly swapped: the 
anisole is oriented against the I helix, and the sulfonamide arene is positioned close to the B' 
helix (Supplementary Figure 8). Residues that make contact with the ligand in both orientations 
include L75, A87, L181, L263, A264, E267, V328, and S438. Several of these residues were 
mutated in the evolutionary lineage from P-I263F to P411CHA (residues 87, 263, 267, 328). In 
both orientations, the ligand is contacted on all sides by protein side chains, showing how the 
enzyme may potentially enforce productive binding modes for catalysis. Docking simulations 
performed with varying Fe–N bond lengths (1.8 Å to 2.4 Å) also produced similar orientations of 
the ligand.  
 The docking simulations with the heme/R-(4) ligand also show a shift of the heme away 
from the I helix (by up to ~1.5 Å), presumably to minimize clashes between the ligand and helix 
residues. However, substrate binding to P450s is known to induce a movement of the I helix 
away from the heme;25,31 such movement of the protein backbone may be required in these P411 
variants during catalysis. A better understanding of substrate binding modes will require further 
computational or co-crystallization studies. 
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Supplementary Figure 7. Docking of the (R)-4/heme complex into the active site of P411 
variant P-4 A82L A78V F263L, first binding mode. The docked ligand is shown in white; the 
orientation of the heme in the crystal structure is shown in magenta. Distances of closest contact 
between the ligand and active site residues are shown as black dashes. 
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Supplementary Figure 8. Docking of the (R)-4/heme complex into the active site of P411 
variant P-4 A82L A78V F263L, second binding mode. The docked ligand is shown in white; the 
orientation of the heme in the crystal structure is shown in magenta. Distances of closest contact 
between the ligand and active site residues are shown as black dashes. 
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